Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies

Lara Maria Pasetto; Umberto Basso; Albe Ariela Brandes

doi:10.1586/14787210.3.2.167

Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies

Lara Maria Pasetto, Umberto Basso, Albe Ariela Brandes

Istituto Oncologico Veneto

Research output: Contribution to journal › Article

Abstract

Anthracyclines and alkylating agents (ifosfamide, Mitoxana®) are the mainstays of chemotherapy for soft tissue sarcoma and as there is a close correlation between dose-intensity and response, methods should be developed to ameliorate the clinical tolerability of these agents. Improvements in the efficacy of medical treatments for soft tissue sarcomas may derive from old strategies by aiming to counteract the side effects of standard chemotherapy regimes and from new, less toxic, anticancer drugs. This paper reviews the currently available options for reducing the cardiotoxicity of anthracyclines, the role of growth factors and autologous stem cell transplantation in dose-intensification of chemotherapy and also examines the clinical impact of the more promising new agents.

Original language	English
Pages (from-to)	167-178
Number of pages	12
Journal	Expert Review of Anticancer Therapy
Volume	3
Issue number	2
DOIs	https://doi.org/10.1586/14787210.3.2.167
Publication status	Published - Apr 2003

Keywords

Anthracyclines
Cardiotoxicity
Chemotherapy
High-dose chemotherapy
Soft tissue sarcoma
Toxicity

ASJC Scopus subject areas

Cancer Research
Pharmacology

Access to Document

10.1586/14787210.3.2.167

Fingerprint Dive into the research topics of 'Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies'. Together they form a unique fingerprint.

Cite this

Pasetto, L. M., Basso, U., & Brandes, A. A. (2003). Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies. Expert Review of Anticancer Therapy, 3(2), 167-178. https://doi.org/10.1586/14787210.3.2.167

@article{ab9a31ee52e24e9b85b6809b6ead4df7,

title = "Improved tolerability of chemotherapy in soft tissue sarcomas: Old and new strategies",

abstract = "Anthracyclines and alkylating agents (ifosfamide, Mitoxana{\textregistered}) are the mainstays of chemotherapy for soft tissue sarcoma and as there is a close correlation between dose-intensity and response, methods should be developed to ameliorate the clinical tolerability of these agents. Improvements in the efficacy of medical treatments for soft tissue sarcomas may derive from old strategies by aiming to counteract the side effects of standard chemotherapy regimes and from new, less toxic, anticancer drugs. This paper reviews the currently available options for reducing the cardiotoxicity of anthracyclines, the role of growth factors and autologous stem cell transplantation in dose-intensification of chemotherapy and also examines the clinical impact of the more promising new agents.",

keywords = "Anthracyclines, Cardiotoxicity, Chemotherapy, High-dose chemotherapy, Soft tissue sarcoma, Toxicity",

author = "Pasetto, {Lara Maria} and Umberto Basso and Brandes, {Albe Ariela}",

year = "2003",

month = apr,

doi = "10.1586/14787210.3.2.167",

language = "English",

volume = "3",

pages = "167--178",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - Improved tolerability of chemotherapy in soft tissue sarcomas

T2 - Old and new strategies

AU - Pasetto, Lara Maria

AU - Basso, Umberto

AU - Brandes, Albe Ariela

PY - 2003/4

Y1 - 2003/4

N2 - Anthracyclines and alkylating agents (ifosfamide, Mitoxana®) are the mainstays of chemotherapy for soft tissue sarcoma and as there is a close correlation between dose-intensity and response, methods should be developed to ameliorate the clinical tolerability of these agents. Improvements in the efficacy of medical treatments for soft tissue sarcomas may derive from old strategies by aiming to counteract the side effects of standard chemotherapy regimes and from new, less toxic, anticancer drugs. This paper reviews the currently available options for reducing the cardiotoxicity of anthracyclines, the role of growth factors and autologous stem cell transplantation in dose-intensification of chemotherapy and also examines the clinical impact of the more promising new agents.

AB - Anthracyclines and alkylating agents (ifosfamide, Mitoxana®) are the mainstays of chemotherapy for soft tissue sarcoma and as there is a close correlation between dose-intensity and response, methods should be developed to ameliorate the clinical tolerability of these agents. Improvements in the efficacy of medical treatments for soft tissue sarcomas may derive from old strategies by aiming to counteract the side effects of standard chemotherapy regimes and from new, less toxic, anticancer drugs. This paper reviews the currently available options for reducing the cardiotoxicity of anthracyclines, the role of growth factors and autologous stem cell transplantation in dose-intensification of chemotherapy and also examines the clinical impact of the more promising new agents.

KW - Anthracyclines

KW - Cardiotoxicity

KW - Chemotherapy

KW - High-dose chemotherapy

KW - Soft tissue sarcoma

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0037394273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037394273&partnerID=8YFLogxK

U2 - 10.1586/14787210.3.2.167

DO - 10.1586/14787210.3.2.167

M3 - Article

C2 - 12722876

AN - SCOPUS:0037394273

VL - 3

SP - 167

EP - 178

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -